Market downturn spurs Molecular Partners to postpone an IPO while Proteon takes a discount; Actavis pays $40M for buyout option;

@FierceBiotech: J&J heads to Texas with its R&D farm system, scouting for biotech startups. News | Follow @FierceBiotech

@JohnCFierce: Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro, a Fierce 15 company. News | Follow @JohnCFierce

@DamianFierce: Inbox: "FDA Encourages Juice Safety This Fall"; juice safely, everyone. | Follow @DamianFierce

@EmilyMFierce: Sigh. US midterm elections offer little hope for science. More from Nature | Follow @EmilyMFierce

> Swiss biotech Molecular Partners--a Fierce 15 company--has delayed its planned $159 million IPO, citing adverse market conditions. "We would've weakened the company by pursuing the IPO," Chief Executive Officer Christian Zahnd told Bloomberg. "Until Monday everything looked fine but with the market downturn, investors got more risk averse." Story

> Proteon Therapeutics in Waltham, MA, was forced to take a discount price on its shares to complete their IPO. The biotech sold shares at $10 each, well below the $12 to $14 range, in another example of the bifurcation between the good, the bad and the ugly among biotech IPOs these days. Story

> Actavis ($ACT) has inked an option to buy Rhythm Health, a Boston-based biotech developing relamorelin (RM-131), a peptide ghrelin agonist designed to treat diabetic gastroparesis and other GI functional disorders. Actavis paid a $40 million upfront to clinch the deal. Release

> Lyon, France-based EryTech has raised 30 million euros to fund the clinical development of its experimental drugs designed to "starve" cancer tumors. Release

Medical Device News

@FierceMedDev: Mobile blood glucose monitor startup Telcare gets $33M round. Article | Follow @FierceMedDev

@VarunSaxena2: Sanofi leads $11M Series A round for needle-free delivery company. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: U.S. Department of Homeland Security investigating cybersecurity concerns for devices from $MDT, $STJ and $HSP. More | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain. FierceDrugDelivery article | Follow @MichaelGFierce

> Private insurers squeezing device companies in bid to limit costs. More

> Enigma Diagnostics eyes China market with $50M and a JV. Article

Pharma News

@FiercePharma: Top-read in FP Wednesday: $GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots. Article | Follow @FiercePharma

@CarlyHFierce: Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines. FierceVaccines item | More from FiercePharmaMarketing | Follow @CarlyHFierce

> Medicines Company sues lawyers for busting Angiomax patent filing deadline. Story

> Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. More

> Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla. Article

Vaccines News

> Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe. More

> GSK taps Slaoui to chair flat-selling vaccines unit with an eye to the future. Story

> Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines. Item

> Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late. More

> FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine. Article

Pharma Manufacturing News

> Roche, too, has big plans for improved HQ facilities. Item

> Industry faces new effort to make it pay for drug disposal. More

> Repackager mistakenly puts some ibuprofen bottles into naproxen boxes. Report

> GSK manufacturing will take hit in cost-cutting move. Story

> Argos starts work on $57M plant in North Carolina. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.